Santarus is a specialty pharmaceutical company that is focused on acquiring, developing and commercializing proprietary products that treat gastrointestinal diseases and disorders. Its products are immediate-release formulations of omeprazole, a widely prescribed proton pump inhibitor. The company's marketed products include ZEGERID capsules and ZEGERID powder for oral suspension. Santarus received United States Food and Drug Administration approval for its third dosage form, ZEGERID with Magnesium Hydroxide chewable tablets, in March 2006. These products are the first and only immediate-release oral PPIs approved by the U.S. Food and Drug Administration for commercial sale in the U.S.